COPD Treatment Studies Progressing for Cannabis Science Inc (OTCMKTS:CBIS)

3342

Cannabis Science Inc (OTCMKTS:CBIS) has been an item of interest for us for quite some time, for its research into cannabinoids and the various medical benefits they can convey. The last time we mentioned it we were talking about the company receiving clearance to take government contracts for marijuana research.

Today we’re focused on the research the company already has underway, which according to CBIS is nearing the point where clinical trials could begin soon on a treatment for a disease that affects many Americans.

This week Cannabis Science Inc (OTCMKTS:CBIS) has announced that its research staff is nearing completion of a novel new cannabinoid formulary to treat the Asthma and Chronic Obstructive Pulmonary Disease (COPD) Overlap Syndrome (ACOS) with clinical trials to follow upon completion.

“Our new formulary will target four aspects of COPD inflammation, airway constriction, capacity, and anxiety. Cannabinoid extracts have many unique properties as well as an inflammatory agent these extracts also do aid in controlling anxiety and it is our belief lung capacity. The strain we are working with is one that has lung expansion properties, this certain strain chemical makeup causes the lungs to expand or hyper-inflate once the dose has been administered and over a subscribed to therapy term is expected to build back lung muscle strength in the weakened lungs along with increased volume capacity as the lungs are stressed much like breathing exercises would do for the patient that no longer has the ability to effectively do deep breathing exercises,” stated Chief Medical Officer: Dr. Allen Herman.

 

 

“This is an immense market segment, with approximately 5 million people with diagnosed cases of COPD in the United States alone and the 20 % prevalence of the Asthma, COPD Overlap Syndrome offers a known market of approximately 5 million doses per month potential for CBIS’ new formula.We are looking to provide both short-term relief and long-term therapy addressing the Asthma aspect of the syndrome, and will provide the needed support for the COPD aspect targeting inflammation, constriction, anxiety, and panic, which often times leads to ER visits and potentially longer hospital stays. The ability of Cannabis extracts to give patients the calming effect offered in a non-opioid form of medication will help calm patients and allow the other ingredients time to work before a full-fledged panic attack ensues thereby multiplying the symptoms present,” stated Cannabis Science, Inc., President & CEO, Co-Founder Mr. Raymond C. Dabney.

The Company is interviewing test subjects for clinical trials of this new formulary now, the criteria being used is patients using supplemental oxygen with SpO2 (blood oxygen saturation level) under 95 % with oxygen and under 87% without oxygen. The goal of this trial is to observe for the SpO2 levels to increase over the period of the trial as well as mental health by way of easing anxiety associated with Asthma/COPD flare-ups, this trial is to monitor the effects of various cannabinoid levels and combinations with the patients who were chosen. The Company has other trials in planning to follow this that will include different combinations of cannabinoids designed to target lung capacity and anxiety as well. (Source: Marketwired)

Meanwhile, on the CBIS chart, the PPS has been in a nearly continual incline for the entire month of November so far, so in addition to the company’s interesting research, there are also technical reasons for being interested in following the CBIS story. Keep it locked on Street Register for updates, and we’ll deliver important developments on CBIS as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in CBIS stock, short or long.

LEAVE A REPLY